+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H1 2019

  • ID: 4760058
  • Drug Pipelines
  • 115 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Biogen Inc
  • Celgene Corp
  • Genentech Inc
  • Lead Pharma Holding BV
  • Maruho Co Ltd
  • MORE
Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Pipeline Review, H1 2019

Summary

According to the recently published report 'Nuclear Receptor ROR Gamma - Pipeline Review, H1 2019'; Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) pipeline Target constitutes close to 40 molecules. Out of which approximately 38 molecules are developed by companies and remaining by the universities/institutes.

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - RAR-related orphan receptor gamma (RORγ) is a protein encoded by the RORC gene. RORγ is member of the nuclear receptor family of transcription factors. It exist in two isoforms RORγ and RORγt. RORγ is expressed in many tissues, including thymus, lung, liver, kidney, muscle, and brown fat. R ORγt, appears to be highly restricted to the thymus. RORγ isoform is involved in the regulation of circadian rhythms and RORγt plays an important regulatory role in thymopoiesis and in inhibiting apoptosis.

The report 'Nuclear Receptor ROR Gamma - Pipeline Review, H1 2019' outlays comprehensive information on the Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase II, Phase I, Preclinical, Discovery and Unknown stages are 3, 6, 20, 8 and 1 respectively.

Similarly, the universities portfolio in Preclinical stages comprises 2 molecules, respectively. Report covers products from therapy areas Immunology, Central Nervous System, Gastrointestinal, Oncology, Musculoskeletal Disorders, Respiratory, Dermatology, Metabolic Disorders and Ophthalmology which include indications Psoriasis, Rheumatoid Arthritis, Autoimmune Disorders, Inflammation, Multiple Sclerosis, Inflammatory Bowel Disease, Non-Alcoholic Steatohepatitis (NASH), Plaque Psoriasis (Psoriasis Vulgaris), Psoriatic Arthritis, Adenocarcinoma Of The Gastroesophageal Junction, Allergies, Ankylosing Spondylitis (Bekhterev's Disease), Arthritis, Asthma, Bladder Cancer, Breast Cancer, Chronic Obstructive Pulmonary Disease (COPD), Encephalomyelitis, Esophageal Cancer, Gastric Cancer, Head And Neck Cancer Squamous Cell Carcinoma, Keratoconjunctivitis Sicca (Dry Eye), Kidney Cancer (Renal Cell Cancer), Liver Fibrosis, Metastatic Transitional (Urothelial) Tract Cancer, Neuromyelitis Optica (Devic’s Syndrome), Non-Small Cell Lung Cancer, Ovarian Cancer, Solid Tumor, Systemic Lupus Erythematosus and Type 1 Diabetes (Juvenile Diabetes).

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The report provides a snapshot of the global therapeutic landscape for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • The report reviews Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics and enlists all their major and minor projects
  • The report assesses Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
  • The report summarizes all the dormant and discontinued pipeline projects
  • The report reviews latest news and deals related to Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) targeted therapeutics
Reasons to buy
  • Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand the targeted therapy areas and indications for Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC)
  • Identify the use of drugs for target identification and drug repurposing
  • Identify potential new clients or partners in the target demographic
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
  • Devise corrective measures for pipeline projects by understanding Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) development landscape
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Biogen Inc
  • Celgene Corp
  • Genentech Inc
  • Lead Pharma Holding BV
  • Maruho Co Ltd
  • MORE
Introduction

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Overview

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Development

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Therapeutics Assessment

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Companies Involved in Therapeutics Development

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Drug Profiles

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Dormant Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Discontinued Products

Nuclear Receptor ROR Gamma (Nuclear Receptor RZR Gamma or Nuclear Receptor Subfamily 1 Group F Member 3 or RAR Related Orphan Receptor C or Retinoid Related Orphan Receptor Gamma or RORC) - Product Development Milestones

Appendix

List of Tables

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Indications, H1 2019

Number of Products under Development by Companies, H1 2019

Products under Development by Companies, H1 2019

Number of Products under Investigation by Universities/Institutes, H1 2019

Products under Investigation by Universities/Institutes, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Stage and Route of Administration, H1 2019

Number of Products by Stage and Molecule Type, H1 2019

Pipeline by AbbVie Inc, H1 2019

Pipeline by Allergan Plc, H1 2019

Pipeline by AstraZeneca Plc, H1 2019

Pipeline by Aurigene Discovery Technologies Ltd, H1 2019

Pipeline by Beijing Hanmi Pharmaceutical Co Ltd, H1 2019

Pipeline by Biogen Inc, H1 2019

Pipeline by Boston Pharmaceuticals Inc, H1 2019

Pipeline by Brickell Biotech Inc, H1 2019

Pipeline by Bristol-Myers Squibb Co, H1 2019

Pipeline by Celgene Corp, H1 2019

Pipeline by Daiichi Sankyo Co Ltd, H1 2019

Pipeline by Escalier Biosciences BV, H1 2019

Pipeline by Genentech Inc, H1 2019

Pipeline by Genfit SA, H1 2019

Pipeline by Glenmark Pharmaceuticals Ltd, H1 2019

Pipeline by Johnson & Johnson, H1 2019

Pipeline by Lead Pharma Holding BV, H1 2019

Pipeline by LEO Pharma A/S, H1 2019

Pipeline by Lycera Corp, H1 2019

Pipeline by Novartis AG, H1 2019

Pipeline by Nuevolution AB, H1 2019

Pipeline by Orphagen Pharmaceuticals Inc, H1 2019

Pipeline by Pfizer Inc, H1 2019

Pipeline by Reata Pharmaceuticals Inc, H1 2019

Pipeline by SK Chemicals Co Ltd, H1 2019

Pipeline by Takeda Pharmaceutical Co Ltd, H1 2019

Pipeline by Visionary Pharmaceuticals Inc, H1 2019

Dormant Products, H1 2019

Discontinued Products, H1 2019

List of Figures

Number of Products under Development by Stage of Development, H1 2019

Number of Products under Development by Therapy Areas, H1 2019

Number of Products under Development by Top 10 Indications, H1 2019

Number of Products by Mechanism of Actions, H1 2019

Number of Products by Stage and Mechanism of Actions, H1 2019

Number of Products by Routes of Administration, H1 2019

Number of Products by Stage and Routes of Administration, H1 2019

Number of Products by Molecule Types, H1 2019

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Allergan Plc
  • AstraZeneca Plc
  • Aurigene Discovery Technologies Ltd
  • Beijing Hanmi Pharmaceutical Co Ltd
  • Biogen Inc
  • Boston Pharmaceuticals Inc
  • Brickell Biotech Inc
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Daiichi Sankyo Co Ltd
  • Escalier Biosciences BV
  • Genentech Inc
  • Genfit SA
  • Glenmark Pharmaceuticals Ltd
  • Johnson & Johnson
  • Lead Pharma Holding BV
  • LEO Pharma A/S
  • Lycera Corp
  • Maruho Co Ltd
  • Novartis AG
  • Nuevolution AB
  • Orphagen Pharmaceuticals Inc
  • Pfizer Inc
  • Reata Pharmaceuticals Inc
  • SK Chemicals Co Ltd
  • Takeda Pharmaceutical Co Ltd
  • Visionary Pharmaceuticals Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Order Online - visit: https://www.researchandmarkets.com/reports/4760058
Adroll
adroll